Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 6/2014

Open Access 01-12-2014 | Commentary

Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice

Authors: Morton Scheinberg, Gilberto Castañeda-Hernández

Published in: Arthritis Research & Therapy | Issue 6/2014

Login to get access

Abstract

Biosimilars that were not compared in clinical trials with the compound innovator are not true biosimilars (biocopies) and are associated with risks that the clinical rheumatologist should be aware of before generalized use. This article comments on various aspects surrounding the use of such biocopies in clinical rheumatology.
Literature
1.
Kuek A, Hazleman BL, Ostör AJ: Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007, 83: 251-260. 10.1136/pgmj.2006.052688.PubMedCentralCrossRefPubMed
2.
De Piano LP, Golmia RP, Scheinberg MA: Decreased need of large joint replacement in patients with rheumatoid arthritis in a specialized Brazilian center. Clin Rheumatol. 2011, 30: 549-550. 10.1007/s10067-010-1629-6.CrossRefPubMed
3.
Thalayasingam N, Isaacs JD: Anti-TNF therapy. Best Pract Res Clin Rheumatol. 2011, 25: 549-567. 10.1016/j.berh.2011.10.004.CrossRefPubMed
4.
Mota LM, Cruz BA, Brenol CV, Pereira IA, Rezende-Fronza LS, Bertolo MB, Freitas MV, Silva NA, Louzada-Junior P, Giorgi RD, Lima RA, Bernardo WM, Pinheiro Gda R: Guidelines for the drug treatment of rheumatoid arthritis. Rev Bras Reumatol. 2013, 53: 158-183. 10.1590/S0482-50042013000200004.CrossRefPubMed
5.
Mikhail A, Farouk M: Epoetin biosimilars in Europe: five years on. Adv Ther. 2013, 30: 28-40. 10.1007/s12325-012-0072-2.CrossRefPubMed
6.
Scheinberg MA, Kay J: The advent of biosimilar therapies in rheumatology - “O brave new world”. Nat Rev Rheumatol. 2012, 8: 430-436. 10.1038/nrrheum.2012.84.CrossRefPubMed
7.
Dorner T, Strand V, Castaneda-Hernandez G, Ferracioli G, Isaacs JD, Kviem TK, Martin-Mola E, Mittendorf T, Smolen JJ, Burmester GR: The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 2013, 72: 322-328. 10.1136/annrheumdis-2012-202715.CrossRefPubMed
8.
Beck A, Reichert JM: Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs. 2013, 5: 621-623. 10.4161/mabs.25864.PubMedCentralCrossRefPubMed
9.
Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, Mikazane H, Gutierrez-Ureña S, Lim M, Lee YA, Lee SJ, Kim H, Yoo DH, Braun J: A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013, 72: 1605-1612. 10.1136/annrheumdis-2012-203091.PubMedCentralCrossRefPubMed
10.
Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, Kovalenko V, Prodanovic N, Abello-Banfi M, Gutierrez-Ureña S, Morales-Olazabal L, Tee M, Jimenez R, Zamani O, Lee SJ, Kim H, Park W, Müller-Ladner U: A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013, 72: 1613-1620. 10.1136/annrheumdis-2012-203090.PubMedCentralCrossRefPubMed
11.
Scheinberg MA: Biosimilars in Crohn’s disease. J Crohns Colitis. 2014, 8: 710-10.1016/j.crohns.2013.12.002.CrossRefPubMed
12.
Scheinberg MA, Azevedo VF: Biosimilars in rheumatology: perspective and concerns. Rheumatology (Oxford). 2014, 53: 389-390. 10.1093/rheumatology/ket210.CrossRef
13.
Mysler E, Scheinberg MA: Biosimilars in rheumatology: a view from Latin America. Clin Rheumatol. 2012, 31: 1279-1280. 10.1007/s10067-012-2068-3.CrossRefPubMed
14.
15.
16.
de Guzman GC, Khaleghi M, Riffenberg RH, Clark RF: A survey of the use of foreign-purchased medications in a border community emergency department patient population. J Emerg Med. 2007, 33: 213-221. 10.1016/j.jemermed.2007.02.019.CrossRefPubMed
17.
Metadata
Title
Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
Authors
Morton Scheinberg
Gilberto Castañeda-Hernández
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 6/2014
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-014-0501-5

Other articles of this Issue 6/2014

Arthritis Research & Therapy 6/2014 Go to the issue

Research article

Demonstration of extracellular peptidylarginine deiminase (PAD) activity in synovial fluid of patients with rheumatoid arthritis using a novel assay for citrullination of fibrinogen

Editorial

Targeting subchondral bone in osteoporotic osteoarthritis

Research article

Quadriceps arthrogenic muscle inhibition: the effects of experimental knee joint effusion on motor cortex excitability

Research article

Local intra-articular injection of rapamycin delays articular cartilage degeneration in a murine model of osteoarthritis

Editorial

Gluten-free diet in the management of patients with irritable bowel syndrome, fibromyalgia and lymphocytic enteritis

Research article

Constitutively altered frequencies of circulating follicullar helper T cell counterparts and their subsets in rheumatoid arthritis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits